Korro Bio, a Cambridge biotechnology firm, said Thursday it has raised more than $90 million in venture capital to advance its technology to repair genetic mutations that cause a variety of diseases.
The startup, which was founded in 2018 by Cambridge venture capital firm Atlas Venture, hopes to treat disorders through RNA editing, a cutting-edge approach that makes changes to the molecular messengers that create proteins implicated in various illnesses.
